{"id":"aza-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL499186","moleculeType":"Protein","molecularWeight":"1031.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting myeloperoxidase, AZA capsules reduce the production of reactive oxygen species, which can damage tissues and contribute to various inflammatory and autoimmune diseases. This mechanism is thought to be beneficial in conditions such as ulcerative colitis and Crohn's disease.","oneSentence":"AZA capsules work by inhibiting the enzyme myeloperoxidase, which is involved in the production of reactive oxygen species.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:08.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe ulcerative colitis"},{"name":"Moderate to severe Crohn's disease"}]},"trialDetails":[{"nctId":"NCT07071155","phase":"EARLY_PHASE1","title":"Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-19","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms","enrollment":18},{"nctId":"NCT04256317","phase":"PHASE2, PHASE3","title":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2020-05-21","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm","enrollment":316},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":24},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT07439211","phase":"PHASE1","title":"Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2026-07","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT07435636","phase":"PHASE2","title":"Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis","status":"NOT_YET_RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2026-04-13","conditions":"Clonal Cytopenia of Uncertain Significance, CCUS Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis","enrollment":80},{"nctId":"NCT06782542","phase":"PHASE2","title":"Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy","status":"RECRUITING","sponsor":"Justin Watts, MD","startDate":"2026-05-01","conditions":"Acute Myeloid Leukemia, IDH1 Mutation","enrollment":16},{"nctId":"NCT07271303","phase":"NA","title":"A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-01","conditions":"Painless Gastrointestinal Endoscopy","enrollment":74},{"nctId":"NCT07006025","phase":"PHASE1","title":"A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Treebough Therapies","startDate":"2025-06-03","conditions":"MDS","enrollment":20},{"nctId":"NCT07303660","phase":"PHASE1","title":"A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients","status":"NOT_YET_RECRUITING","sponsor":"Lomond Therapeutics Holdings, Inc.","startDate":"2026-01-10","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":414},{"nctId":"NCT04581512","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Tolerability of EP0042","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2020-11-02","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes","enrollment":70},{"nctId":"NCT05155709","phase":"PHASE1","title":"A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-17","conditions":"Acute Myeloid Leukemia","enrollment":14},{"nctId":"NCT04257448","phase":"PHASE1, PHASE2","title":"Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2020-05-25","conditions":"Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":75},{"nctId":"NCT05019430","phase":"EARLY_PHASE1","title":"Cocaine and Zolmitriptan","status":"COMPLETED","sponsor":"William Stoops","startDate":"2021-10-15","conditions":"Cocaine Use Disorder","enrollment":12},{"nctId":"NCT02719574","phase":"PHASE1, PHASE2","title":"Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation","status":"COMPLETED","sponsor":"Forma Therapeutics, Inc.","startDate":"2016-04-30","conditions":"Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":336},{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT05040464","phase":"PHASE3","title":"Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-08-26","conditions":"Crohn Disease, Azathioprine, Methotrexate","enrollment":166},{"nctId":"NCT05816356","phase":"PHASE1","title":"To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males","status":"COMPLETED","sponsor":"EpiDestiny, Inc.","startDate":"2023-03-24","conditions":"Healthy","enrollment":10},{"nctId":"NCT05506865","phase":"PHASE4","title":"Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2012-09","conditions":"COPD","enrollment":73},{"nctId":"NCT06841952","phase":"NA","title":"Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-02-15","conditions":"AML, Adult","enrollment":158},{"nctId":"NCT02103478","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2014-10-28","conditions":"Myelodysplastic Syndrome, MDS","enrollment":130},{"nctId":"NCT06532058","phase":"PHASE2","title":"Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Changzhou Qianhong Bio-pharma Co., Ltd.","startDate":"2023-08-10","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)","enrollment":53},{"nctId":"NCT05524857","phase":"PHASE1","title":"Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)","status":"TERMINATED","sponsor":"Joseph Jurcic","startDate":"2022-01-28","conditions":"Myeloproliferative Neoplasm","enrollment":2},{"nctId":"NCT03999723","phase":"PHASE2","title":"Combining Active and Passive DNA Hypomethylation","status":"RECRUITING","sponsor":"Kirsten Grønbæk","startDate":"2019-09-11","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":196},{"nctId":"NCT04243785","phase":"PHASE1","title":"A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Edgewood Oncology Inc.","startDate":"2020-01-06","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":80},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT06254664","phase":"PHASE1","title":"Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-10-03","conditions":"COPD","enrollment":116},{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT06232473","phase":"PHASE4","title":"Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2024-01-01","conditions":"Functional Disorder","enrollment":424},{"nctId":"NCT00239447","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":131},{"nctId":"NCT00388882","phase":"PHASE4","title":"Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-10-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":327},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00274560","phase":"PHASE3","title":"A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-05-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":653},{"nctId":"NCT02543879","phase":"PHASE1","title":"Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"Forma Therapeutics, Inc.","startDate":"2015-09","conditions":"Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":94},{"nctId":"NCT03684811","phase":"PHASE1, PHASE2","title":"A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation","status":"COMPLETED","sponsor":"Forma Therapeutics, Inc.","startDate":"2018-11-01","conditions":"Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma","enrollment":93},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT05911126","phase":"NA","title":"How to Reduce Pain in Patients Undergoing Office Hysteroscopy.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-06-13","conditions":"Pain","enrollment":180},{"nctId":"NCT05823701","phase":"PHASE2","title":"Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-09-30","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":23},{"nctId":"NCT05797948","phase":"NA","title":"GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-07-01","conditions":"Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03937986","phase":"EARLY_PHASE1","title":"Suvorexant and Cocaine","status":"COMPLETED","sponsor":"William Stoops","startDate":"2019-07-11","conditions":"Cocaine Use Disorder","enrollment":8},{"nctId":"NCT05048615","phase":"PHASE2","title":"Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2021-07-26","conditions":"AML","enrollment":15},{"nctId":"NCT03842839","phase":"NA","title":"Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2018-10-01","conditions":"Airway Remodeling","enrollment":100},{"nctId":"NCT01303796","phase":"PHASE3","title":"A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Cyclacel Pharmaceuticals, Inc.","startDate":"2011-10-01","conditions":"Acute Myeloid Leukemia","enrollment":482},{"nctId":"NCT02538744","phase":"PHASE1","title":"Complementary Combination Therapy for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2015-08","conditions":"Cocaine Dependence","enrollment":45},{"nctId":"NCT03151408","phase":"PHASE3","title":"An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Helsinn Healthcare SA","startDate":"2017-06-23","conditions":"Acute Myeloid Leukemia","enrollment":406},{"nctId":"NCT03151304","phase":"PHASE2","title":"A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"Helsinn Healthcare SA","startDate":"2017-06-01","conditions":"Myelodysplastic Syndromes","enrollment":64},{"nctId":"NCT02203474","phase":"PHASE2","title":"A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT04716114","phase":"PHASE3","title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-03-24","conditions":"Acute Myeloid Leukemia (AML)","enrollment":315},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT01176903","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":65},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3686},{"nctId":"NCT02319369","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2014-11-25","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":74},{"nctId":"NCT05061147","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)","status":"UNKNOWN","sponsor":"Maxinovel Pty., Ltd.","startDate":"2021-09-16","conditions":"Leukemia, Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT04761952","phase":"NA","title":"N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2021-02-13","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Polyunsaturated Acid Lipidosis","enrollment":236},{"nctId":"NCT02586649","phase":"PHASE2","title":"24hr Effects of Tiotropium Bromide in Tetraplegia","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2014-07","conditions":"Spinal Cord Injury","enrollment":10},{"nctId":"NCT04520230","phase":"PHASE4","title":"Three Treatment of Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2014-10-31","conditions":"COPD","enrollment":45},{"nctId":"NCT00946647","phase":"PHASE1, PHASE2","title":"A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12-02","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":113},{"nctId":"NCT02541006","phase":"PHASE4","title":"Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2014-11","conditions":"COPD","enrollment":58},{"nctId":"NCT04086238","phase":"PHASE1","title":"Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects","status":"COMPLETED","sponsor":"EpiDestiny, Inc.","startDate":"2019-10-08","conditions":"Healthy","enrollment":46},{"nctId":"NCT01545947","phase":"PHASE1","title":"Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-05-01","conditions":"Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT03945344","phase":"PHASE1","title":"Effect of Charcoal on Gastrointestinal Absorption of Tiotropium","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-05-27","conditions":"Healthy Volunteer Study","enrollment":20},{"nctId":"NCT02566031","phase":"PHASE4","title":"A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-23","conditions":"COPD","enrollment":379},{"nctId":"NCT02522325","phase":"PHASE1","title":"Reinforcing Effects of Cocaine During Phendimetrazine Maintenance","status":"COMPLETED","sponsor":"William Stoops","startDate":"2015-08","conditions":"Cocaine Use Disorder","enrollment":30},{"nctId":"NCT03519022","phase":"EARLY_PHASE1","title":"Behavioral Effects of Drugs: Inpatient (35)","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2018-06-01","conditions":"Cocaine Use Disorder","enrollment":9},{"nctId":"NCT02918266","phase":"PHASE1","title":"TAK-071 Scopolamine-Induced Cognitive Impairment Study","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-11-21","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT02033707","phase":"PHASE1","title":"Effects of Hallucinogens and Other Drugs on Mood and Performance","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT03828084","phase":"PHASE1","title":"Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects","status":"COMPLETED","sponsor":"EpiDestiny, Inc.","startDate":"2019-04-03","conditions":"Healthy","enrollment":16},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT03333824","phase":"PHASE1","title":"Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-01","conditions":"Solid Tumours","enrollment":33},{"nctId":"NCT02847000","phase":"EARLY_PHASE1","title":"p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer","status":"COMPLETED","sponsor":"Yogen Saunthararajah","startDate":"2016-12-20","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":13},{"nctId":"NCT02846935","phase":"EARLY_PHASE1","title":"p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies","status":"COMPLETED","sponsor":"Yogen Saunthararajah","startDate":"2017-04-25","conditions":"T-cell Lymphoma, Aggressive B-cell Lymphoma, Non-Hodgkin's Lymphomas","enrollment":7},{"nctId":"NCT03745261","phase":"PHASE3","title":"Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT01213355","phase":"PHASE1","title":"Scopolamine Challenge Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-04","conditions":"Healthy","enrollment":38},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT01662986","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01663987","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT02172443","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT02172794","phase":"PHASE3","title":"Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT01937390","phase":"","title":"Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":645},{"nctId":"NCT02194088","phase":"PHASE3","title":"Combined Medication for Improved Analgesia in Superficial Pain","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2014-04","conditions":"Pain","enrollment":100},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT00157235","phase":"PHASE3","title":"Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":234},{"nctId":"NCT01566773","phase":"PHASE2","title":"PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT02018926","phase":"PHASE1, PHASE2","title":"Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2013-12","conditions":"Myelodysplastic Syndrome","enrollment":18},{"nctId":"NCT00555022","phase":"PHASE1","title":"Effect of GSK1160724 In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":21},{"nctId":"NCT01137890","phase":"PHASE1, PHASE2","title":"Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-06","conditions":"Cocaine Dependence","enrollment":19},{"nctId":"NCT00515502","phase":"PHASE2","title":"Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":24},{"nctId":"NCT02242305","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-11-01","conditions":"Abdominal Pain","enrollment":302},{"nctId":"NCT03169504","phase":"PHASE3","title":"Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2017-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":150},{"nctId":"NCT01715311","phase":"PHASE4","title":"Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT02125734","phase":"PHASE4","title":"Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AZA capsules","genericName":"AZA capsules","companyName":"Centre Hospitalier Universitaire, Amiens","companyId":"centre-hospitalier-universitaire-amiens","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZA capsules are used in clinical trials for the treatment of Non-Small-Cell Lung Cancer and Chronic Obstructive Pulmonary Disease. AZA capsules are also used in combination with other treatments, such as erlotinib, for the treatment of Advanced Non-Small Cell Lung Cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}